Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Add Yahoo as a preferred source to see more of our stories on Google. With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The ...

The Covid-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

A new study suggests mRNA coronavirus vaccines effectively prolonged the lives of certain cancer patients. The study, published Wednesday in the journal Nature, examined health records of patients who ...

A single-dose multicomponent mRNA vaccine elicits durable immune responses against influenza and COVID-19 in a Phase 1/2 trial.

The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

A lawmaker compared getting the vaccine with using meth. The Idaho Medical Association said his bill would infringe on ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.